Psoriasis, Second Edition

Cover -- Half Title Page -- Title Page -- Copyright Page -- Contents -- Preface -- Contributors -- Chapter 1: The History of Psoriasis -- Biblical Times -- First Century A.D. -- The Renaissance Period -- Evolution of Modern Therapies -- Biological Agents -- Conclusion -- References -- Chapter 2: Epidemiology -- Introduction -- Incidence of Psoriasis -- Prevalence of Psoriasis -- Effects of Ethnicity -- Gender -- Age -- Future Directions -- References -- Chapter 3: Microscopic Findings -- The "Evolution" of Psoriasis -- Chronic Plaque Psoriasis -- Guttate Psoriasis -- Erythrodermic Psoriasis -- Follicular Psoriasis -- Inverse Psoriasis -- Nail Psoriasis -- Pustular Psoriasis -- Palmoplantar Pustulosis -- Antitumor Necrosis Factor Alphainduced Psoriasis -- Verrucous Psoriasis -- Psoriatic Alopecia -- References -- Chapter 4: Genetics -- Introduction -- Mode of Inheritance -- Psoriasis Susceptibility Locus 1 -- Variants Driving Psoriasis Gwas Signals -- Protein Coding Alterations Associated with Psoriasis -- Pathways to Psoriasis Identified through Gwas -- Alterations of Components of the Epidermal Barrier in Psoriasis -- Genes of the Epidermal Differentiation Complex -- CARD14 -- Generalized Pustular Psoriasis -- Rare Variants Leading to Psoriasis -- Genetic Contribution to Disease Severity and Age at Onset -- Conclusion -- Acknowledgments -- References -- Chapter 5: Immunology -- Introduction -- T Cells in Psoriasis -- Integral Role of T Cells in Psoriasis Pathogenesis -- T Cells in Normal Skin -- T Cells in Psoriatic Lesion -- Regulatory T Cells -- Dendritic Cells Interplaying with T cells -- Dermal Myeloid Dendritic Cells -- Plasmacytoid Dendritic Cells -- Langerhans Cells -- Innate Immune Cells in Psoriasis -- Neutrophils -- Macrophages -- Natural Killer and NKT Cells -- Psoriatic Cytokines -- IL-17 -- IL-23 -- IFN-[gamma] -- TNF-[alpha]

Immune Pathway Models of Psoriasis -- Conclusions -- References -- Chapter 6: Other environmental risk factors -- Infection -- Medication -- Psychological Distress -- Cigarette Smoking -- Sunshine -- Alcohol Misuse -- Trauma -- References -- Chapter 7: Plaque-Type Psoriasis-Chronic Plaque, Guttate, and Erythrodermic Phenotypes -- Plaque-Type Psoriasis -- Introduction -- Chronic Plaque Psoriasis -- Clinical Symptoms -- Guttate Psoriasis -- Erythrodermic Psoriasis -- References -- Chapter 8: Palmoplantar psoriasis -- Localized Pustular Psoriasis -- Palmoplantar Pustular Psoriasis -- Acrodermatitis Continua of Hallopeau -- Palmoplantar Plaque Psoriasis -- Introduction -- Epidemiology -- Etiopathogenesis -- Clinical Presentation -- Dermatopathology -- Differential Diagnosis -- Treatment -- Summary -- References -- Chapter 9: Generalized Pustular Psoriasis -- Introduction -- Definition, Clinical Presentation, Histopathological, and Biological Findings -- Epidemiology -- Physiopathology -- Clinical Course, Complications, Prognosis -- Treatment -- Conclusion -- References -- Chapter 10: Inverse Psoriasis and Genital Disease -- Clinical Presentation -- Genital Psoriasis -- Differential Diagnoses -- Immunopathology -- Treatment of Inverse and Genital Psoriasis -- Conclusion -- References -- Chapter 11: Nail Psoriasis -- Introduction -- Epidemiology and Prevalence -- Quality of Life -- Clinical Features of Nail Psoriasis -- Assessment of Nail Psoriasis Severity -- Management of Nail Psoriasis -- References -- Chapter 12: Differential Diagnoses of Psoriasis -- Introduction -- Chronic Plaque Psoriasis -- Tinea Corporis -- Discoid Eczema -- Mycosis Fungoides -- Subacute Cutaneous Lupus Erythematosis -- Lichen Planus -- Localised Plaque Psoriasis -- Superficial Basal Cell Carcinoma -- Bowen's Disease -- Contact Dermatitis -- Actinic Keratosis

Extramammary Paget's Disease -- Guttate Psoriasis -- Pityriasis Rosea -- Pityriasis Versicolor -- Secondary Syphilis -- Pityriasis Lichenoides -- Mycosis Fungoides -- Erythrodermic Psoriasis -- Pityriasis Rubra Pilaris -- Allergic Contact Dermatitis -- Atopic Dermatitis -- Chronic Actinic Dermatitis -- Cutaneous T-cell Lymphoma (sezary Syndrome) -- Drug Eruption -- Pustular Psoriasis -- Acute Generalized Exanthematous Pustulosis -- Drug Eruption -- Tinea Pedis -- Flexural Psoriasis -- Intertrigo -- Candidosis -- Erythrasma -- Tinea Cruris -- Contact Dermatitis -- Hailey-hailey Disease -- Scalp Psoriasis -- Contact Dermatitis -- Atopic Dermatitis -- Seborrheic Dermatitis -- Nail Psoriasis -- Onychomycosis -- Lichen Planus -- Alopecia Areata -- Contact Dermatitis -- Palmoplantar Psoriasis -- Pityriasis Rubra Pilaris -- Tinea Pedis -- Contact Dermatitis -- Acrokeratosis Neoplastica (bazex Syndrome) -- Lichen Planus -- Darier's Disease -- Porokeratosis of Mibelli -- Juvenile Plantar Dermatosis -- Genital Psoriasis -- Seborrheic Dermatitis -- Contact Dermatitis -- Lichen Planus -- Lichen Sclerosus -- Plasma Cell Balanitis (zoon's Balanitits, Balanitis Circumscripta Plasmacellularis) -- Plasma Cell Vulvitis (vulvitis Circumscripta Plasmacellularis) -- Bowen's Disease -- Erythroplasia of Queyrat -- Extramammary Paget's Disease -- External Ear Psoriasis -- Seborrheic Dermatitis -- Atopic Dermatitis -- Contact Dermatitis -- Otitis Externa -- Facial Psoriasis -- Seborrheic Dermatitis -- Lupus Erythematosus -- Contact Dermatitis -- Atopic Dermatitis -- Rosacea -- Final Comments/conclusion -- References -- Chapter 13: Genetics, Immunology, and Pathogenesis -- Epidemiology -- Etiology -- Genetic Susceptibility -- Environmental Factors -- Risk Factors in Patients with Skin Psoriasis -- Immunology -- Cellular Involvement -- Inflammatory Cytokines -- Other Mediators

Immunohistopathology -- Pathogenesis -- Summary -- References -- Chapter 14: Psoriatic Arthritis: Clinical Manifestations -- Introduction -- Clinical Concepts -- Clinical Manifestations -- Types of Arthropathy -- Pauciarthritis -- Polyarthritis -- Dip Disease -- Axial Disease -- Arthritis Mutilians -- Enthesitis -- Dactylitis -- Other Clinical Features -- Conclusion -- References -- Chapter 15: Pediatric Psoriasis -- Epidemiology -- Clinical Presentation -- Comorbidities -- Obesity and Cardiovascular Risk -- Joint Complaints -- Other Complaints -- Screening for Comorbidities -- Therapeutic Options -- Topical Therapy (see Chapter 21) -- Phototherapy (see Chapter 22) -- Systemic Therapy (see Chapters 23 and 24) -- References -- Chapter 16: Cardiometabolic Comorbidities -- Cardiometabolic Diseases: Overview -- Obesity -- Dysglycemia -- Dyslipidemia -- Atherosclerotic Cardiovascular Diseases -- The Role of Inflammation in Cardiometabolic Diseases -- Chronic Systemic Inflammation in Psoriasis -- Skin Inflammation -- Blood Inflammation -- Adipose Inflammation -- Vascular Inflammation -- Psoriasis and Cardiovascular Diseases -- Epidemiological Studies -- Translational Studies -- Psoriasis, Obesity and Diabetes -- Epidemiological Studies -- Translational Studies -- Psoriasis Treatment and Effect on Cardiometabolic Diseases -- Epidemiological Studies -- Ongoing Studies -- Recommendation for Screening and Treatment of Cardiometabolic Diseases in Psoriasis -- Conclusions -- References -- Chapter 17: Psychiatric Comorbidities -- Introduction -- Psychosocial Stress -- Anxiety and Social Phobia -- Depression -- Suicidal Ideation -- Alexithymia -- Substance Use -- Alcohol -- Smoking -- Sexual Dysfunction -- Schizophrenia -- Obsessive-Compulsive Disorder -- Personality Disorders -- Somatization and Somatoform Disorders -- Eating Disorders -- Conclusion -- References

Chapter 18: Other Disease Associations: Liver, Gastrointestinal, Respiratory, and Neoplastic -- Introduction -- Gastrointestinal Comorbidity -- Inflammatory Bowel Disease -- Epidemiological Correlation -- Genetic Correlations -- Pathologic Correlations -- Celiac Disease -- Microscopic Colitis -- Alterations in Intestinal Structure and Permeability -- Liver -- Nonalcoholic Fatty Liver Disease -- Cholangitis and Cholestasis -- Psoriasis and Lung Comorbidity -- Infectious Pneumonia -- Interstitial Lung Disease -- Pulmonary Fibrosis -- Chronic Obstructive Pulmonary Disease -- Pulmonary Hypertension -- Acute Respiratory Distress Syndrome -- Psoriasis and Cancer -- Conclusions -- References -- Chapter 19: Assessment and Measurement of Disease -- Introduction -- Assessment in Day-to-day Practice -- The Importance of Thorough Measurement and Assessment -- Body Surface Area: a Misunderstood Variable of Assessment -- Clinician-assessed Measurement Tools -- Psoriasis Area and Severity Index -- Physician's Global Assessment -- Psoriasis Subtypes -- Nonplaque Psoriasis Subtypes -- Psoriatic Arthritis -- Patient-report Measurement Tools -- Psoriasis-specific Tools -- Psoriasis Disability Index -- Psoriasis Life Stress Inventory -- Psoriasis Index of Quality of Life -- General Dermatologic and Generic Hrqol Assessment Tools -- Dermatology Life Quality Index -- Skindex -- Short-form 36 -- Combined Measurement Tools -- Salford Psoriasis Index -- Koo-menter Psoriasis Instrument -- The Comprehensive Assessment of the Psoriasis Patient: a Comprehensive Measurement Tool -- References -- Chapter 20: Current and future Topical Treatments for Psoriasis -- Introduction -- Topical Corticosteroids -- Vitamin D Analogs -- Tazarotene -- Calcineurin Inhibitors -- Anthralin/dithranol -- Coal Tar -- Salicylic Acid -- Novel Therapies -- Wbi-1001 -- E804 -- Crisaborole -- Inc8018424

Tofacitinib